Instituto de Investigación de Enfermedades Raras (IIER)

Permanent URI for this collectionhttps://hdl.handle.net/20.500.12105/19616

El Instituto de Investigación de Enfermedades Raras (IIER), forma parte de la estructura del Instituto de Salud Carlos III (ISCIII) desde noviembre de 2003 bajo la dependencia de la Subdirección General de Servicios Aplicados, Formación e Investigación. La Orden Ministerial de creación del IIER contempla un área denominada Unidad de Investigación del Síndrome del Aceite Tóxico (UISAT), aunque en la práctica funciona con tres unidades: Enfermedades Raras, Trastornos del Espectro del Autismo y Epidemiología de las enfermedades relacionadas con el ambiente, y se coordina con el Centro de Investigación en Anomalías Congénitas (CIAC) en lo referente a estas patologías. El IIER es un Centro Colaborador de la OMS en epidemiología de las enfermedades relacionadas con el ambiente, oficialmente designado por esta organización para estos fines desde el año 1996.

Browse

Recent Submissions

Now showing 1 - 20 of 304
  • Item type: Publication ,
    Health-related quality of life in adults with epidermolysis bullosa: a cross-sectional study in seven European countries using EQ-5D-5L.
    (Springer Nature, 2026-03-19) Linertová, Renata; Péntek, Márta; Rodríguez-Díaz, Benjamín; Bodemer, Christine; Hübl, Vinzenz; El Hachem, May; Salamon, Gudrun; Alonso-Ferreira, Veronica; Stefanov, Georgi; Jain, Ritu; Ramallo-Fariña, Yolanda; García-Pérez, Lidia; Unión Europea. Comisión Europea. H2020; Instituto de Salud Carlos III; DEBRA; National Research, Development and Innovation Office (Hungria)
    Background: Epidermolysis bullosa (EB) is a rare genetic disorder that causes extreme skin fragility, chronic pain, and functional impairment, with major psychosocial and economic consequences. Health-related quality of life (HRQoL) data is critical to capture the full burden of EB. Health utilities derived from preference-based generic instruments such as the EQ-5D-5L provide standardized health status utility values that enable cross-disease comparisons and provide input data for cost-utility analyses to inform resource allocation. There is a notable lack of multinational, up-to-date utility data for EB. This cross-sectional study aimed to assess HRQoL in adults with EB across seven European countries (Austria, Bulgaria, Germany, Hungary, Italy, France, and Spain) using the EQ-5D-5L. Results: A total of 328 adults with EB participated in the survey, 61% were female, 37% were between 18 and 30 years old and 46% had dystrophic EB. Based on self-reported symptoms, 58% were classified as severe EB. Pain/discomfort was the most affected EQ-5D-5L dimension (92% reporting problems; 27% severe or extreme). The mean EQ-5D value (health utility) was 0.63 (SD 0.32), ranging from 0.57 in Spain to 0.71 in Bulgaria. Patients with severe EB reported significantly lower utilities than non-severe cases (0.52 vs. 0.78, p < 0.001). Mean EQ VAS score was 60 (SD 23.2). Compared to general population norms, EB patients in all countries had markedly lower HRQoL (p < 0.005), with large effect sizes for the EQ-5D value (Cohen's d ≥ 0.8). Symptomatic burden and functional deterioration were the primary drivers of HRQoL impairments. Conclusions: This multinational study provides the most extensive and current health utility data for adults with EB in Europe. Findings reveal the profound HRQoL impairment in EB, particularly in severe cases. These standardized utility values fill a major evidence gap, supporting their use in health economic evaluations, cross-disease comparisons, and policy development.
  • Item type: Publication ,
    Primary biliary cholangitis mortality in Europe: a temporal and spatial view across the period 2002-2022.
    (Springer Nature, 2026-06-25) Ortega-Torres, Angelica; Sánchez-Díaz, Germán; Villaverde-Hueso, Ana; Arias-Merino, Greta; Alonso-Ferreira, Veronica; Instituto de Salud Carlos III
    Background: Primary biliary cholangitis (PBC) is a rare autoimmune disease of multifactorial origin with an uneven incidence across countries. This study sought to identify temporal trends in PBC mortality and describe possible spatial patterns across Europe. Methods: Data on PBC mortality (ICD-10 K74.3) and European populations by age group in 20 countries were sourced from the World Health Organization for the period 2002-2022. We calculated age-adjusted mortality rates (AAMR) for the period 2012-2022, both for individual countries and overall. Trends were assessed using Joinpoint regression analysis. To ascertain the geographical distribution, standardised mortality ratios (SMR) were calculated for the periods 2002-2011 and 2012-2022. Results: A total of 12,934 PBC deaths (81.65% women) were recorded during the period 2002-2022. Mortality showed a downward trend in most countries except for Hungary, Türkiye, Romania and Poland. Lithuania registered the highest AAMR, at 3.47 per 1,000,000 population (95% CI 2.86-4.19), followed by Hungary and the United Kingdom (UK). During the period 2002-2011, the risk of death in northern countries was twice as high as expected (Finland, Lithuania and the UK with SMRs of 2.09 to 2.14). The differences between northern and southern Europe persisted during 2012-2022, albeit with some variations. Conclusions: PBC mortality is decreasing or remains stable in most European countries. Risk of death is higher in countries in the north and north-west. There is a need for further in-depth study of the causes of the geographical variability detected.
  • Item type: Publication ,
    Human Bronchial Epithelial Cell Transcriptome Changes in Response to Serum from Patients with Different Status of Inflammation.
    (Springer Nature, 2024-04) Sivaraman, Kokilavani; Liu, Bin; Martinez-Delgado, Beatriz; Held, Julia; Büttner, Manuela; Illig, Thomas; Volland, Sonja; Gomez-Mariano, Gema Maria; Jedicke, Nils; Yevsa, Tetyana; Welte, Tobias; DeLuca, David S; Wrenger, Sabine; Olejnicka, Beata; Janciauskiene, Sabina; German Center for Lung Research (Alemania); National Science Centre (Polonia)
    Purpose: To investigate the transcriptome of human bronchial epithelial cells (HBEC) in response to serum from patients with different degrees of inflammation. Methods: Serum from 19 COVID-19 patients obtained from the Hannover Unified Biobank was used. At the time of sampling, 5 patients had a WHO Clinical Progression Scale (WHO-CPS) score of 9 (severe illness). The remaining 14 patients had a WHO-CPS of below 9 (range 1-7), and lower illness. Multiplex immunoassay was used to assess serum inflammatory markers. The culture medium of HBEC was supplemented with 2% of the patient's serum, and the cells were cultured at 37 °C, 5% CO2 for 18 h. Subsequently, cellular RNA was used for RNA-Seq. Results: Patients with scores below 9 had significantly lower albumin and serum levels of E-selectin, IL-8, and MCP-1 than patients with scores of 9. Principal component analysis based on 500 "core genes" of RNA-seq segregated cells into two subsets: exposed to serum from 4 (I) and 15 (II) patients. Cells from a subset (I) treated with serum from 4 patients with a score of 9 showed 5566 differentially expressed genes of which 2793 were up- and 2773 downregulated in comparison with cells of subset II treated with serum from 14 patients with scores between 1 and 7 and one with score = 9. In subset I cells, a higher expression of TLR4 and CXCL8 but a lower CDH1, ACE2, and HMOX1, and greater effects on genes involved in metabolic regulation, cytoskeletal organization, and kinase activity pathways were observed. Conclusion: This simple model could be useful to characterize patient serum and epithelial cell properties.
  • Item type: Publication ,
    Functional and clinical significance of novel SERPINA1 variants on alpha-1 antitrypsin deficiency.
    (Springer Nature, 2026-01-30) Matamala, Nerea; Osaba, Lourdes; Drobnic, Estrella; Gil-Martín, Sara; Martin-Galiano, Antonio Javier; Almadana-Pacheco, Virginia; Cazorla, Maria Jesús; Costa, Fabio; Souza-Sokoloski, Caroline; Çörtük, Mustafa; Serra-Fortuny, Mireia; Ortiz-de Saracho, Juan; Lloret-Queraltó, Juan Antonio; Rodriguez-Lázaro, Nuria; Michel-de la Rosa, Francisco Javier; Rodríguez-Hermosa, Juan Luis; Saldaña-Pérez, Leonardo; Akıncı, Elif; Alonso, Javier; Benitez-Buelga, Carlos; Gomez-Mariano, Gema Maria; López-Campos, José Luis; Martinez-Delgado, Beatriz; Grifols (Spain)
    Background: Mutations in the SERPINA1 gene can result in alpha-1 antitrypsin deficiency (AATD), which may be associated with lung or liver injury. Although the S and Z alleles account for over 95% of cases of AATD, a wide variety of rare variants have been linked to deficiency and dysfunction, while other variants are associated with normal alpha-1 antitrypsin (AAT) levels and activity. Here, we present the identification and characterization of thirteen rare SERPINA1 variants discovered during the genetic diagnosis of AATD by the Progenika diagnostic network. Methods: The new variants were identified by sequencing the exons of SERPINA1 gene in cases with discrepancies between AAT serum levels and initial genotyping. In order to determine their pathogenic impact, the variants were expressed in a cellular model and evaluated for AAT secretion, intracellular accumulation and elastase inhibitory activity. In addition, protein structural mapping of the variants and analysis of positioning and residue/atomic contacts were performed. Results: The in silico and functional in vitro analysis allowed us to classify these AAT variants as six deficient (p.Val234Glu, p.Val242_Pro243insLeu, p.Leu291Phe, p.Ala308Ser, p.Pro393Thr and p.Pro393Arg), one dysfunctional (p.Thr96Ile), three normal (p.Ser71Arg, p.Ala349Pro and p.Asp365Glu) and three null alleles (p.Gln33*, p.Gln285* and p.Leu310Phefs*14). Conclusions: Functional assays and protein structural information are useful tools in the characterization of novel variants of the SERPINA1 gene. The newly characterized mutations expand the number of SERPINA1 variants with proven pathogenic effects, facilitating the diagnoses of future cases of AATD.
  • Item type: Publication ,
    De novo EHMT2 variants cause an autosomal dominant EHMT2-related Kleefstra syndrome via loss of G9a methyltransferase activity.
    (Springer Nature, 2026-07-01) Hnízda, Aleš; Martinez-Delgado, Beatriz; Sánchez-Ponce, Diana; Alonso, Javier; Amiel, Jeanne; Attie-Bitach, Tania; Bada-Navarro, Ariadna; Baladron-Jimenez, Beatriz Isabel; Bermejo-Sanchez, Eva; Brinsa, Vítězslav; Buková, Ivana; Cazorla-Calleja, Rosario; Červenková, Sylvie; Chow, Shanshan; Dušek, Petr; Fedosieieva, Olha; Fernandez-Prieto, Marta; Ghosh, Sourav; Gomez-Mariano, Gema Maria; Gřegořová, Andrea; Hamilton, Mark James; Hartmannová, Hana; Hernandez-SanMiguel, Esther; Herrero-Matesanz, Marina; Hodaňová, Kateřina; Kádek, Alan; Kerkhof, Jennifer; Kleefstra, Tjitske; Lacombe, Didier; Levy, Michael A; Lopez-Martin, Estrella; Lyse, Ruaud; Man, Petr; Marin-Reina, Purificacion; Macnamara, Ellen F; McConkey, Haley; Melenovská, Petra; Mirela Mielu, Lidia; Moore, David; Steiner Mrázová, Lenka; Musilová, Karolína; Neffeová, Kristýna; Nickl, Petr; Pajuelo Reguera, David; Pavlíková, Martina; Pavlovičová, Lea; Posada De la Paz, Manuel; Procházka, Jan; Pysanenko, Kateryna; Ramos-Del Saz, Sheila; Rots, Dmitrijs; Rzasa, Jessica; Sedláček, Radislav; Stránecký, Viktor; Špoutil, František; Tedder, Matthew L; Thompson, Louise; Tifft, Cynthia J; Tran Mau-Them, Frederic; Trešlová, Helena; Vitobello, Antonio; Hilton, Sarah; Campbell, Christopher; Banka, Siddharth; Jirák, Daniel; Sadikovic, Bekim; Sikora, Jakub; Kmoch, Stanislav; Barrero, Maria J; Nosková, Lenka; Unión Europea. Comisión Europea; Fundación Inocente-Inocente; Instituto de Salud Carlos III; Ministerio de Ciencia, Innovación y Universidades (España)
    EHMT1 and EHMT2 genes encode human euchromatin histone lysine methyltransferase 1 and 2 (EHMT1 alias GLP; EHMT2 alias G9a) that form heteromeric GLP/G9a complexes with essential roles in epigenetic regulation of gene expression. While EHMT1 haploinsufficiency has been established as the cause of Kleefstra syndrome 1, the pathogenesis of G9a dysfunction in human disease remains largely unknown. We identified seven de novo EHMT2 variants in patients with clinical presentation, episignatures, histone modifications and transcriptomic profiles similar to those of Kleefstra syndrome 1. In vitro studies reveal that these variants encode for structurally stable G9a proteins that are catalytically incompetent due to aberrant interactions either with histone H3 tail or with S-adenosylmethionine. Heterozygous mice carrying a patient-derived variant exhibit growth retardation, facial/skull dysmorphia and aberrant behavior. Here we report pathogenic EHMT2 variants that likely exert dominant-negative effect on GLP/G9a complexes and thus genocopy the EHMT1 haploinsufficiency via a distinct molecular mechanism, defining an autosomal dominant EHMT2-related Kleefstra syndrome.
  • Item type: Publication ,
    Sur8/Shoc2 como nuevo actor en envejecimiento y fragilidad (SENFRA-2). Data Management Plan V1.0.
    (Instituto de Salud Carlos III (ISCIII). Instituto de Investigación de Enfermedades Raras (IIER), 2026-06-23) Casas-Tinto, Sergio; Instituto de Salud Carlos III
    El proyecto SENFRA-2, se enmarca en una iniciativa colaborativa y multidisciplinar de cinco grupos del ISCIII orientada a investigar el papel de Sur8/Shoc2 como un nuevo regulador molecular implicado en los procesos de envejecimiento y fragilidad. A partir de evidencias preliminares que identifican a Sur8 como un factor clave en la regulación de la vía Ras/MAPK, altamente conservada evolutivamente, el proyecto combina aproximaciones experimentales en modelos como Drosophila melanogaster, C. elegans, modelos murinos modificados genéticamente y sistemas celulares ex vivo, junto con análisis integrativos de datos multi-ómicos (transcriptómica, microRNA, proteómica, fosfoproteómica y oxidación proteica). Su objetivo es caracterizar los mecanismos biológicos asociados a la alteración de Sur8 y generar conocimiento fundamental sobre los procesos de envejecimiento, estrés oxidativo y fragilidad, identificando posibles biomarcadores candidatos y dianas terapéuticas. En este contexto, el proyecto SENFRA-2 se centra en el uso de Drosophila como modelo experimental ya que permite estudiar de manera eficiente estos procesos debido a la alta conservación genética y la posibilidad de realizar análisis funcionales y de cribado de compuestos en tiempos reducidos. El proyecto presenta una elevada relevancia científica, sanitaria y social, dado que el envejecimiento y la fragilidad constituyen un desafío creciente para los sistemas de salud, asociados a un aumento de la morbilidad, la dependencia y los costes socioeconómicos. La identificación de mecanismos moleculares comunes y la integración de datos multi-ómicos entre especies contribuirán al avance del conocimiento en biología del envejecimiento y podrían, a medio-largo plazo, facilitar el desarrollo de estrategias de diagnóstico temprano, medicina personalizada e intervenciones preventivas. El presente Plan de Gestión de Datos establece los procedimientos relativos al almacenamiento, acceso, preservación, reutilización y protección de los datos generados durante el desarrollo del subproyecto, garantizando su adecuación a los principios FAIR (localizables, accesibles, interoperables y reutilizables) y el cumplimiento de las políticas institucionales del Instituto de Salud Carlos III.
  • Item type: Publication ,
    Identification and functional insights into new phage tail-like bacteriocins targeting as new antimicrobials.
    (American Society for Microbiology (ASM), 2026-03-24) Ibarguren-Quiles, Clara; Blasco, Lucía; López-Causape, Carla; Bleriot, Inés; Fernández-García, Laura; Arman, Lucia; Barrio-Pujante, Antonio; Ortiz-Cartagena, Concha; Aracil, Belen; Menéndez-Rodriguez, Olaya; Mariñas-Pardo, Luis; Cantón, Rafael; Oliver, Antonio; Tomás, María; Instituto de Salud Carlos III; Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF); Centro de Investigación Biomédica en Red - CIBERINFEC (Enfermedades Infecciosas); Ministerio de Ciencia, Innovación y Universidades (España); Unión Europea. Comisión Europea. NextGenerationEU; Xunta de Galicia (España)
    The current health crisis caused by multidrug-resistant (MDR) pathogens is one of the health problems of most concern globally. Infections caused by these pathogens, such as , lead to high rates of complications, particularly in compromised patients such as cystic fibrosis (CF) patients. The need to counteract and minimize the forecast future impact has led to the rescue of phage therapy. The use of bacteriophages has important advantages, including highly specific targeting, self-amplification at the infection site, minimal disruption of the microbiome, safety, and biocompatibility. However, the capacity of bacteria to escape these entities results in a form of resistance that compromises the effectiveness of the therapy. This involves the search for potential alternatives, such as the phage tail-like bacteriocins (PTLBs), also named as tailocins. These high-molecular-weight particles resemble the tail structure of bacteriophages and are characterized by the absence of genetic material, avoiding the development of resistance, one of the major handicaps associated with phage therapy. In this study, we detected 34 different PTLBs in 75 genomes, with different serotypes and sequence types, 11 of which were characterized as novel F-type PTLB subtypes (F13-F24). Furthermore, we report that four selected PTLBs (R1, F15, F19, and R3-F24) can deal with bacterial infection, with the R1 and the F15 PTLBs being the most efficient in clearing infection , yielding a survival rate of more than 75% in the larvae model. This reaffirms the potential of PTLBs to control infections, which can cause chronic infections in some patients, such as people with CF, due to its strong impact as a MDR bacterium.IMPORTANCEThe 75 genomes from people with cystic fibrosis in the study collection included at least one phage tail-like bacteriocins (PTLB) cluster. From the 34 different PTLBs detected in the study collection, 7 were R-type, 10 were complex (R- and F-type encoded), and 14 were F-type PTLBs. Eleven new F-type PTLBs were described in the collection under study. An association between the O-antigen present on the surface of the isolate and the encoded PTLB subtype was detected. The R1 and F15 PTLB subtypes display high antimicrobial activity both in vitro and in vivo (Galleria mellonella).
  • Item type: Publication ,
    Exploring the anti-inflammatory activity of fupenzic acid using network pharmacology and experimental validation.
    (Nature Publishing Group, 2025-04-24) Boukerouis, Djoudi; Cuadrado, Irene; Benaida, Nadjet Debbache; Estévez-Braun, Ana; de Las Heras, Beatriz; Amesty, Angel; Hortelano, Sonsoles; Hortelano, Sonsoles; Instituto de Salud Carlos III; Ministerio de Ciencia e Innovación (España); Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF)
    Crataegus azarolus L. (Rosaceae), commonly known as Mediterranean hawthorn, has long been valued in Traditional Medicine for treating cardiovascular and inflammation-related diseases, including diabetes, cancer, and rheumatism. Pharmacological benefits of Crataegus azarolus L. are notably linked to its anti-inflammatory properties. Fupenzic acid, a pentacyclic triterpene isolated from its leaves, holds significant pharmacological potential that remains elusive. This study investigates the unexplored capacity of fupenzic acid as a promising anti-inflammatory agent. Using a multidisciplinary approach that integrates network pharmacology, molecular docking, in vitro assays, and predictive in silico analyses of drug-like properties, ADME, and toxicity, the mechanisms and properties of fupenzic acid have been elucidated. Network pharmacology analysis identified the potential targets for fupenzic acid, with enrichment analyses revealing key processes like inflammatory response, cytokine signaling, innate immune system, and MAPK cascade regulation. Transcription factors such as RELA, SP1, and NFKB1 were predicted to play crucial roles in its therapeutic effects. PPI network analysis underscored NF-κB as a central hub, linking these pathways to its anti-inflammatory effects. In vitro experiments demonstrated that fupenzic acid effectively suppressed inflammatory mediators like NOS-2 and COX-2, through the NF-κB pathway. Molecular docking further confirmed its favorable interaction with NF-κB, reinforcing its mechanism of action. Additionally, in silico ADMET profiling revealed favorable drug-like properties including pharmacokinetics and toxicity profiles, emphasizing its suitability as a drug candidate. This study represents a major step forward in understanding the therapeutic potential of fupenzic acid, establishing it as a distinctive and promising anti-inflammatory agent. The findings identified it as a pharmacological agent for clinical development targeting inflammation-driven diseases and also provide a foundation for future translational research.
  • Item type: Publication ,
    Dehydroisohispanolone alleviates NLRP3-driven inflammation in gout arthritis.
    (Elsevier, 2025-10) González-Cofrade, Laura; Green, Jack P; de Las Heras, Beatriz; Terencio, María Carmen; Hortelano, Sonsoles; Brough, David; Estévez-Braun, Ana; Ferrándiz, María Luisa; Cuadrado, Irene; Ministerio de Ciencia, Innovación y Universidades (España); Agencia Estatal de Investigación (España); Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF); Instituto de Salud Carlos III
    Natural products constitute an important resource for drug discovery with hispanolone derivatives recognized as bioactive diterpenes due to their broad therapeutic potential. Dehydroisohispanolone (DIH) is an anti-inflammatory labdane diterpene, that acts as a multi-target agent through various inflammation pathways. Aberrant activation of the Nod-like receptor protein 3 (NLRP3) inflammasome is involved in several inflammatory diseases, including gout. This study explores the mechanisms underlying the effects of DIH on the NLRP3 inflammasome and pyroptosis in vitro and evaluates its therapeutic effects on gouty arthritis in mice. DIH suppresses interleukin (IL)-1β secretion and pyroptosis in lipopolysaccharide (LPS)-primed bone-marrow-derived macrophages (BMDMs) elicited by broad stimuli. DIH exerts its action by disrupting adaptor apoptosis-associated speck-like protein (ASC) oligomerization, thereby inhibiting the assembly of inflammasome complex. Notably, DIH specifically inhibits NLRP3 inflammasome activation in murine BMDMs without affecting the absent in melanoma-2 (AIM2) or NOD-like receptor family CARD domain containing 4 (NLRC4) inflammasomes. In animal models, DIH significantly mitigated monosodium urate (MSU)-induced joint inflammation, reducing cytokine levels and myeloperoxidase (MPO) secretion. Overall, this study identified DIH as a specific inhibitor of the NLRP3 inflammasome, providing new insights into its potential as a therapeutic agent for NLRP3-mediated inflammatory diseases.
  • Item type: Publication ,
    p19ARF Deficiency Disrupts Lung and Lipid Homeostasis Resembling the Human Alveolar Proteinosis.
    (Oxford University Press, 2026-02-05) Jimenez-Garcia, Lidia; Pérez-Montero, Andrea; Herranz, Sandra; Luque, Alfonso; Tarín, Carlos; Castillo, Diego; Lopez-Vilaro, Laura; Mariñas-Pardo, Luis; McCarthy, Cormac; Acebo, Paloma; Hortelano, Sonsoles; Instituto de Salud Carlos III; Comunidad de Madrid (España)
    The alternative reading frame (ARF) protein, encoded by the CDKN2A locus, is well-recognized for its role in tumor suppression. Emerging evidence has highlighted ARF as a critical regulator of innate immunity and inflammation, with links to increased susceptibility to cardio-metabolic diseases. This study investigates the role of ARF in lung homeostasis and reveals that its deficiency in mice affects lipid metabolism and leads to pulmonary abnormalities resembling pulmonary alveolar proteinosis (PAP). ARF-deficient mice exhibited abnormal surfactant clearance, characterized by lipid and protein accumulation in the alveoli, foamy alveolar macrophages (AMs) with enlarged and vacuolated morphology, and increased bronchoalveolar lavage fluid (BALF) turbidity. These changes were linked to disrupted surfactant homeostasis resulting from an imbalance between increased lipid uptake (via upregulation of scavenger receptors such as SR-A1 and CD36) and impaired lipid efflux, evidenced by reduced expression of the cholesterol transporter SR-BI. These mice also display reduced AMs numbers, increased eosinophil and neutrophil infiltration, consistent with secondary PAP. Additionally, a distinctive chemokine and cytokine profile (elevated Ccl12, Ccl2, Cxcl1, and IL10) was observed, which may be associated with type 2 immune responses and alternative AMs polarization. Interestingly, ARF deficiency also appears to compromise AMs maintenance through effects on self-renewal and survival. Pulmonary function tests revealed increased tissue elastance and damping, suggesting early-stage lung stiffness. Collectively, these findings highlight the essential role of ARF in lung homeostasis and lipid regulation, providing insights into its potential involvement in PAP pathogenesis.
  • Item type: Publication ,
    Drosophila as a Model for Human Disease: Insights into Rare and Ultra-Rare Diseases
    (Multidisciplinary Digital Publishing Institute (MDPI), 2024-11-06) Casas-Tinto, Sergio
    Rare and ultra-rare diseases constitute a significant medical challenge due to their low prevalence and the limited understanding of their origin and underlying mechanisms. These disorders often exhibit phenotypic diversity and molecular complexity that represent a challenge to biomedical research. There are more than 6000 different rare diseases that affect nearly 300 million people worldwide. However, the prevalence of each rare disease is low, and in consequence, the biomedical resources dedicated to each rare disease are limited and insufficient to effectively achieve progress in the research. The use of animal models to investigate the mechanisms underlying pathogenesis has become an invaluable tool. Among the animal models commonly used in research, Drosophila melanogaster has emerged as an efficient and reliable experimental model for investigating a wide range of genetic disorders, and to develop therapeutic strategies for rare and ultra-rare diseases. It offers several advantages as a research model including short life cycle, ease of laboratory maintenance, rapid life cycle, and fully sequenced genome that make it highly suitable for studying genetic disorders. Additionally, there is a high degree of genetic conservation from Drosophila melanogaster to humans, which allows the extrapolation of findings at the molecular and cellular levels. Here, I examine the role of Drosophila melanogaster as a model for studying rare and ultra-rare diseases and highlight its significant contributions and potential to biomedical research. High-throughput next-generation sequencing (NGS) technologies, such as whole-exome sequencing and whole-genome sequencing (WGS), are providing massive amounts of information on the genomic modifications present in rare diseases and common complex traits. The sequencing of exomes or genomes of individuals affected by rare diseases has enabled human geneticists to identify rare variants and identify potential loci associated with novel gene-disease relationships. Despite these advances, the average rare disease patient still experiences significant delay until receiving a diagnosis. Furthermore, the vast majority (95%) of patients with rare conditions lack effective treatment or a cure. This scenario is enhanced by frequent misdiagnoses leading to inadequate support. In consequence, there is an urgent need to develop model organisms to explore the molecular mechanisms underlying these diseases and to establish the genetic origin of these maladies. The aim of this review is to discuss the advantages and limitations of Drosophila melanogaster, hereafter referred as Drosophila, as an experimental model for biomedical research, and the applications to study human disease. The main question to address is whether Drosophila is a valid research model to study human disease, and in particular, rare and ultra-rare diseases.
  • Item type: Publication ,
    Adult neurogenesis through glial transdifferentiation in a CNS injury paradigm.
    (eLife Sciences Publications, 2025-03-07) Casas-Tinto, Sergio; Garcia-Guillen, Nuria; Losada-Perez, María
    As the global population ages, the prevalence of neurodegenerative disorders is fast increasing. This neurodegeneration as well as other central nervous system (CNS) injuries cause permanent disabilities. Thus, generation of new neurons is the rosetta stone in contemporary neuroscience. Glial cells support CNS homeostasis through evolutionary conserved mechanisms. Upon damage, glial cells activate an immune and inflammatory response to clear the injury site from debris and proliferate to restore cell number. This glial regenerative response (GRR) is mediated by the neuropil-associated glia (NG) in , equivalent to vertebrate astrocytes, oligodendrocytes (OL), and oligodendrocyte progenitor cells (OPCs). Here, we examine the contribution of NG lineages and the GRR in response to injury. The results indicate that NG exchanges identities between ensheathing glia (EG) and astrocyte-like glia (ALG). Additionally, we found that NG cells undergo transdifferentiation to yield neurons. Moreover, this transdifferentiation increases in injury conditions. Thus, these data demonstrate that glial cells are able to generate new neurons through direct transdifferentiation. The present work makes a fundamental contribution to the CNS regeneration field and describes a new physiological mechanism to generate new neurons.
  • Item type: Publication ,
    VP3.15, a dual GSK-3β/PDE7 inhibitor, reduces glioblastoma tumor growth though changes in the tumor microenvironment in a PTEN wild-type context.
    (Elsevier, 2025-07) Castello-Pons, Maria; Ramírez-González, María A; Iglesias-Hernandez, Patricia; Lendo, Nermina Logo; Rodriguez-Martin, Carlos; Quiralte, Laura; Sepúlveda-Sánchez, Juan-Manuel; Dios Huerta, Olaya de; Gil, Carmen; Martínez, Ana; Sánchez-Gómez, Pilar; Casas-Tinto, Sergio
    Glioblastoma (GB) is an incurable cancer of the brain, and there is an urgent need to identify effective treatments. This may be achieved by either identifying new molecules or through drug repurposing. To ascertain the therapeutic potential of known GSK-3β and/or PDE7 inhibitors in GB, a drug screening was conducted using a Drosophila melanogaster glioma model. VP3.15, a dual inhibitor with anti-inflammatory and neuroprotective roles in multiple sclerosis, was selected for further investigation. VP3.15 demonstrated robust anti-tumor efficacy against a panel of human and mouse GB cells; however, its capacity to inhibit orthotopic growth was only observed in a wild-type PTEN cell line. The in vivo dependence on PTEN was further suggested with the results in fly gliomas. The analysis of the VP3.15-treated tissues revealed a notable reduction in the number of myeloid cells and in the degree of vascularization. Mechanistic studies indicate that VP3.15 diminishes the production of GAL9, a key molecule that stimulates pro-angiogenic macrophages. Our findings substantiate the pro-tumoral function of GSK-3β, which might depend on the PTEN genetic status. Furthermore, we have delineated the therapeutic potential of VP3.15, which acts through the inhibition of the supportive role of the GB microenvironment. This molecule could be safely and effectively utilized after PTEN characterization in GB patients.
  • Item type: Publication ,
    CRISPR-mediated targeting of the LMNA c.745C>T pathogenic mutation enhances survival and cardiac function in congenital muscular dystrophy.
    (Elsevier, 2025-12) Gomez-Dominguez, Deborah; Epifano, Carolina; Hernández Martínez, Iván; Vilaplana-Marti, Borja; Martin, Alberto; Amarilla-Quintana, Sandra; Cesar, Sergi; de Molina-Iracheta, Antonio; Sena-Esteves, Miguel; Sarquella-Brugada, Georgia; Perez de Castro, Ignacio
    LMNA-associated congenital muscular dystrophy is a currently incurable rare genetic disorder characterized by early-onset muscle weakness, dilated cardiomyopathy and respiratory failure, resulting from mutations in the LMNA gene. In this study, we assessed the potential of a CRISPR-mediated strategy to eliminate the mutant allele Lmna c.745C>T, p.R249W using a mutation specific guide (sg745T). Results from R249W-mutation-carrying cellular models showed specific activity of the Cas9/sg745T complex towards the mutant allele. This property varied depending on the concentration of CRISPR components, with a loss of specificity observed with increased dosage. We tested this strategy in vivo using adeno-associated virus delivery in LmnaR249W mice. Despite being associated with a modest CRISPR activity, this therapeutic approach led to a 10% (non-significant) increase in the survival of R249W homozygous mice. Interestingly, a comparable CRISPR activity significantly ameliorated the cardiac pathology observed in Lmna+/R249W animals, resulting in a significant 24.3% extension of their median survival. These results represent the first therapeutic validation of a CRISPR/Cas9-mediated gene editing strategy for the treatment of LMNA-associated congenital muscular dystrophy.
  • Item type: Publication ,
    Risk of neuroblastoma and residential proximity to industrial and urban sites: A case-control study.
    (Elsevier, 2016-04) García-Pérez, Javier; Morales-Piga, Antonio; Gomez-Barroso, Diana; Tamayo-Uria, Ibon; Pardo Romaguera, Elena; Fernandez-Navarro, Pablo L; Lopez-Abente, Gonzalo; Ramis, Rebeca; Instituto de Salud Carlos III
    Background: Neuroblastoma is the most common extracranial solid tumor in children but its etiology is not clearly understood. While a small fraction of cases might be attributable to genetic factors, the role of environmental pollution factors needs to be assessed. Objectives: To ascertain the effect of residential proximity to both industrial and urban areas on neuroblastoma risk, taking into account industrial groups and toxic substances released. Methods: We conducted a population-based case-control study of neuroblastoma in Spain, including 398 incident cases gathered from the Spanish Registry of Childhood Tumors (period 1996-2011), and 2388 controls individually matched by year of birth, sex, and region of residence. Distances were computed from the respective subject's residences to the 1271 industries and the 30 urban areas with ≥75,000 inhabitants located in the study area. Using logistic regression, odds ratios (ORs) and 95% confidence intervals (95%CIs) for categories of distance (from 1km to 5km) to industrial and urban pollution sources were calculated, with adjustment for matching variables and socioeconomic confounders. Results: Excess risk (OR; 95%CI) of neuroblastoma was detected for the intersection between industrial and urban areas: (2.52; 1.20-5.30) for industrial distance of 1km, and (1.99; 1.17-3.37) for industrial distance of 2km. By industrial groups, excess risks were observed near 'Production of metals' (OR=2.05; 95%CI=1.16-3.64 at 1.5km), 'Surface treatment of metals' (OR=1.89; 95%CI=1.10-3.28 at 1km), 'Mines' (OR=5.82; 95%CI=1.04-32.43 at 1.5km), 'Explosives/pyrotechnics' (OR=4.04; 95%CI=1.31-12.42 at 4km), and 'Urban waste-water treatment plants' (OR=2.14; 95%CI=1.08-4.27 at 1.5km). Conclusions: These findings support the need for more detailed exposure assessment of certain substances released by these industries.
  • Item type: Publication ,
    Risk of bone tumors in children and residential proximity to industrial and urban areas: New findings from a case-control study.
    (Elsevier, 2017-02-01) García-Pérez, Javier; Morales-Piga, Antonio; Gomez-Barroso, Diana; Tamayo-Uria, Ibon; Pardo Romaguera, Elena; Lopez-Abente, Gonzalo; Ramis, Rebeca; Instituto de Salud Carlos III; Asociación Española Contra el Cáncer
    Few epidemiologic studies have explored risk factors for bone tumors in children, and the role of environmental factors needs to be analyzed. Our objective was to ascertain the association between residential proximity to industrial plants and urban areas and risk of bone tumors in children, taking into account industrial groups and toxic pollutants released. A population-based case-control study of childhood bone cancer in Spain was carried out, covering 114 incident cases obtained from the Spanish Registry of Childhood Tumors (between 1996 and 2011), and 684 controls individually matched by sex, year of birth, and autonomous region of residence. Distances from the subject's residences to the 1271 industries and the 30 urban areas (towns) with ≥75,000 inhabitants located in the study area were computed. Unconditional logistic regression models were fitted to estimate odds ratios (ORs) and 95% confidence intervals (95%CIs) for categories of distance (from 1km to 3km) to industrial and urban areas, with adjustment for matching variables and sociodemographic indicators. Excess risk (OR; 95%CI) of bone tumors in children was detected for children close to industrial facilities as a whole (2.33; 1.17-4.63 at 3km) - particularly surface treatment of metals (OR=2.50; 95%CI=1.13-5.56 at 2km), production and processing of metals (OR=3.30; 95%CI=1.41-7.77 at 2.5km), urban waste-water treatment plants (OR=4.41; 95%CI=1.62-11.98 at 2km), hazardous waste (OR=4.63; 95%CI=1.37-15.61 at 2km), disposal or recycling of animal waste (OR=4.73; 95%CI=1.40-15.97 at 2km), cement and lime (OR=3.89; 95%CI=1.19-12.77 at 2.5km), and combustion installations (OR=3.85; 95%CI=1.39-10.66 at 3km)-, and urban areas (4.43; 1.80-10.92). These findings support the need for more detailed exposure assessment of certain toxics released by these facilities.
  • Item type: Publication ,
    Targeted inactivation of EWSR1 : : FLI1 gene in Ewing sarcoma via CRISPR/Cas9 driven by an Ewing-specific GGAA promoter
    (Nature Publishing Group, 2025-04) Cervera Mayor, Saint Thomas; Martinez Rodríguez, Selene; Iranzo-Martínez, Maria; Notario, Laura; Melero-Fernández de Mera, Raquel María; Alonso, Javier; Instituto de Salud Carlos III; Asociación Pablo Ugarte contra el cáncer infantil; Fundación la Sonrisa de Alex para la investigación y el tratamiento del sarcoma de Ewing; Asociación Todos somos Iván; Candela Ribera. Asociación contra el sarcoma de Ewing; Centro de Investigación Biomédica en Red - CIBERER (Enfermedades Raras); Fundación FEDER
    We have recently demonstrated that genetic inactivation of EWSR1 : : FLI1 by CRISPR/Cas9, successfully blocks cell proliferation in a cell model of Ewing sarcoma. However, CRISPR/Cas9-mediated gene editing can exhibit off-target effects, and thus, precise regulation of Cas9 expression in target cells is essential to develop gene-editing strategies to inactivate EWSR1 : : FLI1 in Ewing sarcoma cells. In this study, we demonstrate that Cas9 can be specifically expressed in Ewing sarcoma cells when located downstream a promoter consisting of GGAA repeats and a consensus TATA box (GGAAprom). Under these conditions, Cas9 is selectively expressed in Ewing sarcoma cells that express EWSR1 : : FLI1 oncoproteins, but not in cells expressing wild-type FLI1. Consequently, Ewing sarcoma cells infected with GGAAprom>Cas9 and a specific gRNA designed to inactivate EWSR1 : : FLI1, showed successful EWSR1 : : FLI1 inactivation and the subsequent blockade of cell proliferation. Notably, GGAAprom>Cas9 can be efficiently delivered to Ewing sarcoma cells via adenoviral vectors both in vitro and in vivo, highlighting the potential of this approach for Ewing sarcoma treatment. Our results demonstrate that the CRISPR/Cas9 machinery is safe and specific for Ewing sarcoma cells when driven under a GGAAprom, paving the way for the development of cancer gene therapies based on the selective expression of genes with therapeutic potential.
  • Item type: Publication ,
    Development of newborn screening policies in Spain 2003-2022: what do we actually need to reach an agreement?
    (OAE Publishing, 2023-09-13) Valcárcel-Nazco, Cristina; García-Pérez, Lidia; Linertová, Renata; Guirado-Fuentes, Carmen; Hernández-Yumar, Aránzazu; Paz-Valiñas, Lucinda; Cantero-Muñoz, Paula; Posada De la Paz, Manuel; Serrano-Aguilar, Pedro
    Newborn screening (NBS) for inherited disorders is recognized as an essential public health intervention to improve health outcomes in the newborn population. The implementation of an NBS programme requires an evaluation of effectiveness, safety, cost-effectiveness, feasibility, and budget impact. Determining which of the known disorders should be included in NBS programmes is a public health policy challenge. In this context, economic evaluation aims to contribute to the sustainability of public health systems, but the appropriate economic evaluation framework for these interventions is still unclear. Existing NBS programmes vary widely in the number and type of disorders screened, even among the most developed European countries, despite the fact that the core criteria for guiding policy decision-making are standard. In Spain, where delivery of NBS programmes is marked by heterogeneity between regions, guidelines based on the best available scientific evidence are being established in order to achieve standardization of NBS policies and programmes at a national level. This paper provides a general overview of existing evidence-based health-policy initiatives aimed at enhancing the equity and efficiency of the NBS programme in Spain and their impact on health decisions. We also describe existing challenges to reduce uncertainty, and the variations observed in decisions relating to the content and procedures used in NBS programmes.
  • Item type: Publication ,
    Silicosis mortality in Spain (1999-2020): A temporal and geographical approach
    (AIMS Press, 2024) Sanchez-Diaz, German; Arias-Merino, Greta; Gallego, Elisa; Sarmiento Suárez, Rodrigo; Alonso-Ferreira, Veronica; Instituto de Salud Carlos III
    Background: Silicosis is an occupational respiratory disease linked to silica dust inhalation. The main driver was traditional coal mining, but in recent decades, new sources of exposure have emerged. Our aim in this study was to assess the temporal and spatial distribution of mortality due to this disease over a 22-year period in Spain. Methods: Silicosis records, as an Underlying Cause of Death, were extracted from the National Institute of Statistics from 1999 to 2020 using the International Classification of Diseases 10th revision (code J62.8). Age- and sex-adjusted mortality rates per 1,000,000 inhabitants were calculated for the territory and by province. A geographic analysis was performed, and clusters of deaths were identified at the municipal level, and then the outcomes were compared in two periods of 11 years. Results: There were 2618 deaths due to silicosis in Spain. The mean age of death increased significantly by 0.66% annually from 1999 to 2013. The age-adjusted mortality rate decreased by 7.30% per year, falling from 3.00 to 0.65 per 1,000,000 inhabitants. The temporal pattern showed a significant decrease of mortality rate in 31% of the provinces (16 out of 52), while it increased in Pontevedra. Regarding the spatial analysis, 11 clusters were found in both periods, but some variations were observed in terms of their distribution in the Spanish territory, as well as in the affected municipalities. Conclusions: The decrease in mortality due to Silicosis could be related to less exposure to silica dust over the years and an improvement in the survival of those affected. It is thus essential to analyze the role of preventive measures for this occupational disease.
  • Item type: Publication ,
    Performance of the Idylla microsatellite instability test in endometrial cancer
    (Elsevier, 2024-10) Mendiola, Marta; Heredia-Soto, Victoria; Ruz-Caracuel, Ignacio; Baillo, Amparo; Ramon-Patino, Jorge Luis; Berjon, Alberto; Escudero Ruiz, Francisco Javier; Peláez-García, Alberto; Hernandez, Alicia; Feliu, Jaime; Hardisson, David; Redondo, Andres; Agencia Estatal de Investigación (España); Instituto de Salud Carlos III; Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF)
    Context: DNA mismatch repair (MMR) deficiency (dMMR) testing is now recommended in endometrial cancer. Defect identification in the molecules participating in this pathway, or the presence of microsatellite instability, are commonly employed for this purpose. Novel methods are continuously evolving to report dMMR/microsatellite instability and to easily perform routine diagnoses. Objective: The main aim of this study was to compare the concordance of the Idylla microsatellite instability test for the identification of dMMR endometrial cancer samples defined by immunohistochemistry and MMR genomic status. Design: We applied the Idylla MSI test to 126 early-stage endometrial cancer cases with MMR testing by immunohistochemistry and genomic characterization (methylation in MLH1 and sequence alterations in MLH1, PMS2, MSH2 and MSH6). Individual markers and overall specific performance indicators were explored. Results: The Idylla platform achieved a higher global concordance rate with MMR genomic status than with immunohistochemistry (75 % and 66 %, respectively). Sensitivity and specificity are also higher (75 % vs 66 % and 96 % vs 90 %, respectively). Clustering analysis split the patients into 2 well-differentiated clusters, the pMMR and the dMMR group, represented by MLH1/PMS2 loss and the MLH1 methylated promoter. Overall, immunohistochemistry and MMR genomic status identified more dMMR cases than did the Idylla test, although correlations were improved with a modified Idylla test cut-off. Conclusions: Performance of the Idylla test was better correlated with MMR genomic status than MMR immunohistochemistry status, which improved with a modified test cut-off. Further studies are needed to confirm the cut-off accuracy.